Search - tctmd.com

Displaying 221 - 240 of 480

Sort: Relevancy | Date

Presentation TCT 2017

Rationale and Potential Role for LAA Closure in the PCI and ACS Patient

Presenter: Samir R. Kapadia, Ashish Pershad

November 01, 2017

Presentation TCT 2017

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Pascal Vranckx

November 01, 2017

Presentation TCT 2017

Managing AS Patients With Atrial Fibrillation in TAVR Patients Pharmacotherapy Considerations and LAAC Possibilities (WATCH-TAVR Trial)

Presenter: Samir R. Kapadia

November 01, 2017

Presentation TCT 2017

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Renato D. Lopes

November 01, 2017

Presentation TCT 2017

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

When Bleeding Occurs on Warfarin or NOAC: Reversal Strategies

Presenter: Robert A. Harrington, Kurt Huber, Michael D. Ezekowitz

November 01, 2017

Presentation TCT 2017

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic Atrial Fibrillation Patient Who Requires PCI

Presenter: Robert A. Harrington, Kurt Huber, Christopher B. Granger

November 01, 2017

Presentation TCT 2017

When and Which Antiplatelet Agent Should Be Dropped When Using Oral Anticoagulant Therapy?

Presenter: Robert A. Harrington, Kurt Huber, Roxana Mehran

November 01, 2017

Presentation TCT 2017

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Presenter: Robert A. Harrington, Kurt Huber, Michelle O'Donoghue

November 01, 2017

Presentation TCT 2017

Should the Type of Stent Influence DAPT Decisions in Patients Receiving OAC? Insights From WOEST, LEADERS Free, and More

Presenter: Robert A. Harrington, Kurt Huber, Didier Carrié

November 01, 2017

Presentation TCT 2017

Guidelines and Expert Consensus on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI: How Strong Is the Evidence?

Presenter: Robert A. Harrington, Kurt Huber, Jean-François Tanguay

November 01, 2017

Presentation TCT 2017

What Is (and Is Not) Known About DAPT Decisions in Patients on Chronic Oral Anticoagulants

Presenter: Robert A. Harrington, Kurt Huber, Freek W.A. Verheugt

November 01, 2017

Presentation TCT 2017

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus Antiplatelet Therapy

Presenter: Robert A. Harrington, Kurt Huber, Renato D. Lopes

November 01, 2017

Presentation TCT 2017

TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials

Presenter: Steven R. Bailey, Patrick W. Serruys, Angelo Biviano, MD

November 01, 2017

Presentation TCT 2017

TCT 80: Incidence, Predictors, and Outcomes of New-Onset Atrial Fibrillation and Flutter After PCI or CABG for Left Main Disease: Analysis From the EXCEL Trial

Presenter: Davide Capodanno, Tullio Palmerini, Ioanna Kosmidou

October 31, 2017

Presentation TCT 2017

Case #2 Introduction: 85-Year-Old Patient With Previous Stents and Severe Aortic Stenosis, Reduced LVEF, Chronic Anemia, and Mild Renal Impairment Develops Atrial Fibrillation After TAVR

Presenter: Nick Curzen, Rod H. Stables

October 31, 2017

Presentation TCT 2017

Debate: LAA Closure Should Be Considered in Most Patients With Nonvalvular Atrial Fibrillation!

Presenter: Christopher B. Granger, Horst Sievert, Maurice Buchbinder

October 30, 2017

Presentation TCT 2017

Atrial Fibrillation and PCI/ACS: NOACs, Dual Therapy, and Triple Therapy

Presenter: Thomas H. Maloney, C. Michael Gibson

October 30, 2017

Presentation TCT 2017

Catheter Ablation and/or LAA Closure for Atrial Fibrillation: Competitive or Complementary?

Presenter: Christopher B. Granger, Horst Sievert, Vivek Y. Reddy

October 30, 2017

Advertisement

Rationale and Potential Role for LAA Closure in the PCI and ACS Patient

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Managing AS Patients With Atrial Fibrillation in TAVR Patients Pharmacotherapy Considerations and LAAC Possibilities (WATCH-TAVR Trial)

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

When Bleeding Occurs on Warfarin or NOAC: Reversal Strategies

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic Atrial Fibrillation Patient Who Requires PCI

When and Which Antiplatelet Agent Should Be Dropped When Using Oral Anticoagulant Therapy?

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Should the Type of Stent Influence DAPT Decisions in Patients Receiving OAC? Insights From WOEST, LEADERS Free, and More

Guidelines and Expert Consensus on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI: How Strong Is the Evidence?

What Is (and Is Not) Known About DAPT Decisions in Patients on Chronic Oral Anticoagulants

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus Antiplatelet Therapy

TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials

TCT 80: Incidence, Predictors, and Outcomes of New-Onset Atrial Fibrillation and Flutter After PCI or CABG for Left Main Disease: Analysis From the EXCEL Trial

Case #2 Introduction: 85-Year-Old Patient With Previous Stents and Severe Aortic Stenosis, Reduced LVEF, Chronic Anemia, and Mild Renal Impairment Develops Atrial Fibrillation After TAVR

Debate: LAA Closure Should Be Considered in Most Patients With Nonvalvular Atrial Fibrillation!

Atrial Fibrillation and PCI/ACS: NOACs, Dual Therapy, and Triple Therapy

Catheter Ablation and/or LAA Closure for Atrial Fibrillation: Competitive or Complementary?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content